Plus Therapeutics, Inc.

Rentabilité sur six mois: -74.68%
Rendement en dividendes: 0%
Secteur: Healthcare

0.314 $

+0.004 $ +1.29%
0.27 $
1.9 $

paper.min_max_per_year

Calendrier des promotions Plus Therapeutics, Inc.

À propos de l'entreprise Plus Therapeutics, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Paramètres de base

IPO date
2000-11-16
ISIN
US72941H4002
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 1.22 9
P/BV -0.9896 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -144.03 0
ROE 252.07 10
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.4007 10
Debt/Ratio 0.5076 9
Debt/Equity -1.74 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 63.77 8
Rentabilité Ebitda, % -8.67 0
Rentabilité EPS, % -94.68 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.31 $ 0 $ 0 $ 1.29 % 0 % 0 %
common.calendar.number_days.7d 0.33 $ 0 $ 0 $ -4.85 % 0 % 0 %
common.calendar.number_days.30d 0.3 $ 0.31 $ 0.35 $ 4.67 % 0 % 0 %
common.calendar.number_days.90d 0.75 $ 0.27 $ 0.98 $ -58.13 % 0 % 0 %
common.calendar.number_days.180d 1.24 $ 0.27 $ 1.57 $ -74.68 % 0 % 0 %
common.calendar.number_days.1y 1.43 $ 0.27 $ 1.9 $ -78.04 % 0 % 0 %
common.calendar.number_days.3y 0.87 $ 0.27 $ 7.2 $ -63.91 % 0 % 0 %
common.calendar.number_days.5y 2.6 $ 0.27 $ 7.2 $ -87.92 % 0 % 0 %
common.calendar.number_days.10y 0.13 $ 0.13 $ 19.25 $ 238.46 % 0 % 0 %
common.calendar.number_days.ytd 1.24 $ 0.27 $ 1.57 $ -74.68 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Marc H. Hedrick M.B.A., M.D. President, CEO & Director 945.34k 1963 (62 année)
Mr. Andrew J. Sims CPA VP of Finance & CFO 498.51k 1973 (52 année)
Ms. Desiree Smith Corporate Controller, Principal Financial & Accounting Officer N/A 1964 (61 année)
Dr. John K. Fraser Chief Scientist N/A 1961 (64 année)

Informations sur l'entreprise

Adresse: United States, Austin. TX, 4200 Marathon Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://plustherapeutics.com